Trial: 201903098

A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone (ARROW)

Phase

II

Principal Investigator

Michalski, Jeff

Disease Site

Prostate

Learn more about this study at: clinicaltrials.gov